Drugs / G-CSF
last change Feb 2021 re-read 2 minutes ago

G-CSF

Developed for
dysgammaglobulinemia · myeloid hemopathy · neutropenia · viral infectious disease

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT02231879 Comparator Oct 2014 → Oct 2020 dysgammaglobulinemia, myeloid hemopathy, neutropenia, viral infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as G-CSF ClinicalTrials.gov intervention name — accepted as the source's own label NCT02231879
Route Subcutaneous “Study drugs were both given subcutaneously twice daily for 14 months using unmarked prefilled glass syringes” NCT02231879